Navigation Links
Poorly understood cell plays role in immunity against the flu
Date:3/22/2010

Boston, Mass. A new understanding of a certain cell in the immune system may help guide scientists in creating better flu vaccines, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI). Reporting online March 21 in Nature Immunology, they show, for the first time, that white blood cells known as resident dendritic cells (DCs) capture flu viruses and show them to B-lymphocytes, another white blood cell that recognizes germs and launches an antibody attack. Harnessing this previously unknown function could help activate the immune system more effectively against the flu virus.

"The government is putting a lot of money into vaccine development," says senior investigator Michael Carroll, PhD, director of the immunology graduate program at PCMM/IDI. "A lot of people are thinking about how to target vaccines, and this kind of information will tell us what cell type we would want to target."

Carroll's lab, in collaboration with Shannon Turley of the Department of Cancer Immunology and AIDS at Dana Farber Cancer Institute and Department of Pathology, Harvard Medical School, closely examined what happens when a flu vaccine is injected into mice, a good model for human vaccination. They focused specifically on what happens in the lymph node, where germs and vaccine antigens are filtered.

"We're trying to break down this black box that we know as the lymph node, and identify the different cells that are there, how they interact with each other and what the general rules are," Carroll says. "Then, you can begin to manipulate it to improve vaccines and immune responses."

When it comes to building permanent immunity, B-lymphocytes are the key players because they can remember specific germs and mount a rapid antibody attack. One way B-lymphocytes first encounter germs in the lymph nodes is through the help of macrophages, white blood cells that trap germs and "show" them to B-lymphocytes. For this reason, some researchers believe macrophages to be a prime target in developing a vaccine. Carroll's lab designed their experiment to test this concept for the flu virus and got surprising results.

Working with a mouse model of influenza vaccination, the lab attached fluorescent labels to an inactivated strain of human H1N1 virus, allowing the inactivated flu virus to be tracked in the body. Imaging showed that macrophages trapped the virus in the lymph nodes and prevented most of it from entering the circulation. However, the macrophages did not bring the virus to B-lymphocytes, contrary to what was predicted. Instead, experiments which eliminated the macrophages from the mouse models showed that it was actually the resident DCs in the lymph nodes that were bringing the flu virus to the B-lymphocytes, thus inducing the B-lymphocytes to launch an antibody attack.

To confirm this observation, the researchers injected the mice with an agent to block a specific receptor on the surface of the resident DCs. With this receptor blocked, the B-lymphocytes never sprang into action. When it comes to the flu virus, these results suggest that any targeted vaccine must aim for resident DCs and not macrophages.

"This is the first clear definition of what the resident DCs are doing," Carroll says. The study adds to a growing body of research centered on DCs, which studies continue to show to play a role in stimulating other cells in the immune system.

Targeting influenza vaccines to DCs could make them more effective, Carroll believes. One hypothetical way of doing this would be to attach the virus to an antibody that would home in on the DC cell surface receptor. This method would require further research to confirm the antibody could actually bind to the DC receptor.

In the future, Carroll's lab would like to define a similar immune system pathway for Streptococcus pneumoniae, a bacterium that can cause diseases such as pneumonia, meningitis and middle ear infections.


'/>"/>

Contact: Erin McColgan
erin.mccolgan@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma
2. AGH Study Shows High Rates of Poorly Controlled Asthma Among Inner-City Pittsburgh Children
3. Alcoholics Relapses Better Understood
4. Autism-Related Hypersensitivity Better Understood
5. Genital Herpes Reactivation Better Understood
6. Breast Cancers Spread Now Better Understood
7. Visual Processing Plays Role in Body Dysmorphic Disorder
8. Amerigroup Plays Key Role in Fraud Conviction
9. Playground Surface Plays a Role in Kids Injuries
10. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
11. Selenium Could Shield Against Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: